Loading company
Zura Bio Ltd
ZURA · Nasdaq · ·
$4.00-2.7%Sep 29 close
- 1M
- -29.2%
- 6M
- -33.7%
- 1Y
- -1.0%
ZURA · Nasdaq · ·
$4.00-2.7%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$26.3M | -$16M | -64.47% |
| Profit per share | -$0.21 | -$0.17 | -23.53% |
| Free Cash Flow | $18.9M | $11.1M | +70.47% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Zura Bio Ltd has no earnings call transcript available.
“The second quarter was marked by strong execution across our tibulizumab programs, with enrollment now complete in both TibuSHIELD and TibuSURE—each exceeding its initial enrollment target—underscoring growing conviction in dual IL-17 and BAFF inhibition,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
The quote and the company description come from Zura Bio Ltd’s Item 2.02 8-K filed August 11, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.